GSK sees little prospect of U.S. generic Advair in 2016
May 06, 2015 at 12:32 PM EDT
LONDON, May 6 (Reuters) - After relying for years on its top-selling lung drug Advair, GlaxoSmithKline is now braced for the worst in the form of cheap generics - but not just yet.
